linjc16/ctgov huggingface dataset:
Preoperative Progression of Retinal Detachment

Study Overview
=================
Brief Summary
-----------------
Patients are required to position prior to retinal detachment surgery. We seek to see whether there is a correlation between the performed positioning and retinal detachment progression/regression in fovea-on retinal detachment patients.

Official Title
-----------------
Preoperative Progression of fovea-on Retinal Detachment

Conditions
-----------------
Retinal Detachment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fovea-on retinal detachment informed consent Exclusion Criteria: previous retinal detachment surgery >14 days of retinal detachment symptoms split-fovea retinal detachment other retinal disease with influence on retinal biomechanics/elasticity (proliferative diabetic retinopathy, wet AMD)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal detachment progression/regression | Measured by OCT | 1-72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positioning | Measured by device | 1-72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
positioning
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies

Study Overview
=================
Brief Summary
-----------------
Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to: Diagnostic accuracy using pathologic correlation as gold standard measure Short and long term event free and overall survival

Detailed Description
-----------------
Patients diagnosed with solid malignancies or metastatic lesions who require clinically indicated resection will be identified by their Oncologist. The oncologist will inform the subject/family about the study and ask if they may be interested in participating. If the subject/family demonstrates potential interest in the study, the Pediatric Surgery Research team will discuss the risks and benefits of pre-operative ICG administration with the patients and enrollment. Study subjects: All patients diagnosed with solid malignancies as well as those with metastatic disease distant from the primary tumor will be potentially eligible for the study. Diagnosis will be made: In a multimodal fashion including physical exam, radiologic evaluation (ultrasound, MRI, CT scan, etc), and sometimes biopsy. Prior to definitive surgical resection of the newly diagnosed malignancy

Official Title
-----------------
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid

Conditions
-----------------
Solid Malignancies, Metastatic Disease, Primary Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with newly diagnosed solid, primary malignancies or their related metastatic lesions. Diagnosis of primary or metastatic malignancy will be made by combination of: Clinical evaluation and physical exam Radiologic study including ultrasound, CT scan, and/or MRI Pathologic diagnosis after biopsy Exclusion Criteria: Those patients and parents/guardians unwilling to provide consent/assent. Pregnant and/or women who are breast feeding. Patients with Iodine allergies

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy using pathologic correlation as gold standard measure |  | 2 years | 
| Short and long term event free and overall survival |  | 2 years |
Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the impact of nasal continuous positive airway pressure (nCPAP) treatment on liver enzymes in patients with sleep apnea syndrome and nonalcoholic steatohepatitis. Using a cross over design, the evolution of liver enzymes will be evaluated in 40 patients during a consecutive period of 6 weeks, with and without nCPAP treatment.

Official Title
-----------------
Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis: A Prospective Cross Over Trial

Conditions
-----------------
Sleep Apnea Syndrome, Nonalcoholic Steatohepatitis

Intervention / Treatment
-----------------
* Device: nCPAP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 70 years old Nonalcoholic steatohepatitis proven by liver biopsy Sleep apnea syndrome proven by polysomnography with an apnea-hypopnea index > 10 events/hour Informed consent Exclusion Criteria: Psychiatric disorder Other cause of liver disease Professional driver

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: nCPAP|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage

Study Overview
=================
Brief Summary
-----------------
The study aims to evaluate the suitability of the SOFA score implemented by the Sepsis 3 guideline to detect sepsis in patients suffering from subrarachnoid hemorrhage.

Official Title
-----------------
Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage

Conditions
-----------------
Subarachnoid Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal, Sepsis Syndrome, Sepsis, Sepsis, Severe, Sepsis Bacterial

Intervention / Treatment
-----------------
* Other: Sepsis detection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically ill patients suffering from moderate to severe subarachnoid hemorrhage (WFNS >2). Exclusion Criteria: children under the age of 18 years Patients with minor subarachnoid hemorrhage < WFNS stage 2.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sepsis SOFA positive | Sepsis correctly detected by SOFA score (Sepsis-related organ failure assessment score, 0-24 points) | up to 2 months | 
| Sepsis SOFA negative | Sepsis not detected by SOFA score (Sepsis-related organ failure assessment score, 0-24 points) | up to 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sequential organ failure assessment score
To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines

Study Overview
=================
Brief Summary
-----------------
This study assessed the immunogenicity and safety of two vaccination regimens that employed either GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib vaccine. In the two groups, infants received the DTPa-IPV/Hib vaccine at 3 and 4 months of age, as the first 2 doses of the primary vaccination course. At 5 months of age, they received either the DTPa-IPV/Hib vaccine co-administered with the HBV vaccine or a dose of the DTPa-HBV-IPV/Hib vaccine as a 3rd dose. Infants in the two groups had previously received 2 doses of HBV vaccine at birth and at 1 month of age.

Official Title
-----------------
Phase III, Open, Randomised Immunogenicity and Reactogenicity Study to Assess the Interchangeability Between GSK Bios' DTPa-HBV-IPV/Hib and DTPa-IPV/Hib + HBV at 3rd Dose of Primary Vac. Course in Children Who Received HBV Vac. at Birth and One Month of Age and DTPa-IPV/Hib Vac at 3-4 Mth of Age

Conditions
-----------------
Hepatitis B

Intervention / Treatment
-----------------
* Biological: Infanrix-Hexa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A male or female infant at the age of 11 - 17 weeks. Written informed consent obtained from the parents or guardians of the subject. Free of obvious health problems as established by clinical examination before entering into the study. Hepatitis B vaccine at birth and one month of age. Exclusion Criteria: Previous vaccination against measles, mumps, rubella and/or varicella. Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period. A family history of congenital or hereditary immunodeficiency. Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection. Major congenital defects. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

Ages Eligible for Study
-----------------
Minimum Age: 11 Weeks
Maximum Age: 17 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Infanrix-Hexa|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-HBs conc >=10 mIU/ml, 1 month after the last vaccine dose |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ab conc/titers against all vaccine antigens |  |  | 
| Safety: Solicited symptoms, unsolicited AEs and SAEs |  |  |
Investigation of the Effect of Orthosis Use for Control of Knee Hyperextension in Chronic Stroke Patients

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to examine the effect of using foot-ankle orthosis at different angles on hyperextension control in stroke patients. The hypotheses of the study are: Hypothesis 1: Ho: The foot-ankle orthosis, which fixes the ankle at different angles (3 degrees of dorsiflexion - 5 degrees of dorsiflexion) in stroke patients, has no effect on the control of knee hyperextension. H1: Foot-ankle orthosis, which fixes the ankle at different angles (3 degrees of dorsiflexion - 5 degrees of dorsiflexion) in stroke patients, has an effect on the control of knee hyperextension.

Official Title
-----------------
Investigation of the Effect of Orthosis Use for Control of Knee Hyperextension in Chronic Stroke Patients by Kinematic Analysis

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 40 and 65 Six months must have passed since the stroke. Ambulation regardless of the use of a walking aid (walker, cane, or tripod) Obtaining between 0 and 3 Modified Rankin Score points A score of 24 or higher on the Mini Mental Test is required to pass. Hyperextension during the stance phase of gait. Participating voluntarily in the study Exclusion Criteria: Having a history of more than one stroke Dementia is known to exist Having a diagnosed orthopedic, mental, or neurological condition Having a circumstance that impedes communication Having a history of lower extremity and gait-related surgeries

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic stroke patients with knee hyperextension<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kinematic Analysis | At the specified anatomical sites of the participants, reflective signs will be placed. The participants will be required to walk 5 meters. The three-dimensional positions of these reflective marks will be captured by the 8-camera Vicon motion capture system. Using the blade software, it will be moved to the computer environment and kinematic data will be collected. | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gait Analysis, Foot-Ankle Orthosis, Knee Hyperextension, Kinematic Analysis
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis

Study Overview
=================
Brief Summary
-----------------
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Osteoporosis

Detailed Description
-----------------
This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of Osteoporosis. Patients will receive a single intravenous infusion of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

Official Title
-----------------
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Osteoporosis

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Biological: AlloRx


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Osteoporosis Understanding and willingness to sign a written informed consent document Exclusion Criteria: Active infection Active cancer Chronic multisystem organ failure Pregnancy Clinically significant Abnormalities on pre-treatment laboratory evaluation Medical condition that would (based on the opinion of the investigator) compromise patient's safety. Continued drug abuse Pre-menopausal women not using contraception Previous organ transplant Hypersensitivity to sulfur
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group (AlloRx)<br>Single intravenous infusion of 100 million cells | Biological: AlloRx<br>* cultured allogeneic adult umbilical cord derived mesenchymal stem cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (adverse events) | Clinical monitoring of possible adverse events or complications | Four year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoporosis, stem cell treatment
Pilot Survey of Dengue Fever in Solomon Islands

Study Overview
=================
Brief Summary
-----------------
Since 2009, Kaohsiung Medical University Hospital organized a medical team to provide the medical service for people in Solomon Islands thru Taiwan Health Center at the local. In addition to Malaria and pulmonary tuberculosis, the investigators also found dengue virus, Japanese Encephalitis virus, Chikungunya virus infections and intestinal parasitic infections might be the existing but overlooked and neglected medical issues in Solomon Islands. These infections show similarity in clinical manifestations and usually difficulty in clinical diagnosis, instead these infections rely on the laboratory identification with good laboratory quality and facility.

Detailed Description
-----------------
In this study, the investigators plan to investigate the local people, either from the community or the hospitals, to identify the prevalence and incidence of dengue fever, including laboratory identification of related infections for differential diagnosis, including Japanese Encephalitis virus, Chikungunya virus and intestinal parasitic infections. Intestinal parasite survey has been the routine long-term service offered by the Kaohsiung Medical University Hospital in Solomon Islands. At the same time, the subjects enrolled in this study will also be asked the common medical illness in Solomon Islands (i.e. malaria, pulmonary tuberculosis and metabolic syndrome etc.) in order to delineate the association of dengue fever and these acute and chronic illness.

Official Title
-----------------
Pilot Survey of Dengue Fever in Solomon Islands

Conditions
-----------------
Arbovirus Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteer reported dengue virus infection volunteer people who understand the purpose of the study and agree the to sign the informed consent Exclusion Criteria: people who refuse to join the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Suspected dengue fever subjects<br>No any intervention | |
| Community Healty Residents<br>No intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dengue fever | Clinical manifestations, comorbidity and severity | at the time of sampling (blood) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Co-infection and interplay of dengue-like pathogens | Identification and Analysis of dengue-like illness and pathogens to investigate the interplay between these coinfections | within the first 3 months after blood sampling | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dengue virus
Treatment of Surgical Scars Using the Pulsed Dye Laser

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether treatment of fresh surgical scars with a pulsed dye laser using purpura-inducing settings will improve clinical appearance better than one using non-purpura-inducing settings or no treatment.

Official Title
-----------------
Treatment of Surgical Scars With the 595nm Pulsed Dye Laser Using Purpuric and Nonpurpuric Parameters: A Comparative Study

Conditions
-----------------
Scar, Laser Therapy

Intervention / Treatment
-----------------
* Other: Laser treatment with Purpuric settings
* Other: Laser treatment with Nonpurpuric settings
* Other: No treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients requiring Mohs micrographic surgery or excisions for skin cancer or atypical nevi, with an expected post-excision scar of 4.5cm in length or more. Willing to participate. Able to give informed consent Exclusion Criteria: Location of excision or Mohs surgery on the genitals, hands, or feet. Fitzpatrick skin type V or VI. Prior history of known light sensitivity.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.|
|Other: Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.|
|Other: No treatment|No laser treatment|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vancouver Scar Scale score |  | 6weeks, 10weeks, and 18weeks after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective rating of pain on scale of 0 to 10 |  | at each treatment visit: 2weeks, 6weeks, and 10weeks after surgery | 
| Cosmetic appearance of scar |  | 6weeks, 10 weeks, and 18weeks after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
scar, laser therapy, lasers, pulsed dye